Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Deal: Collaboration or Financing (ascending)
1 2 3 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
3D-MASSOMICS project–EU (govt): grant, 201210– FP7 grant €2.8m 2012-10-30
4 Animals AlsterScience–Hamburg (govt): investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel 2014-10-09
4 Animals AlsterScience–High-Tech Gründerfonds: investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel 2014-10-09
4 Animals AlsterScience–SEVERAL: investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel 2014-10-09
4-Antibody–Advent Venture Partners: investment, 201101 existent listed as current portfolio company of Advent 2011-01-13
4-Antibody–Agenus: investment, 201401–201402 acquisition $10m in 3.3m shares plus milestones that may exceed $40m in cash or shares 2014-01-13
4-Antibody–College Group: public relations, 201109 service existent by College Hill Life Sciences 2011-09-19
4DCellFate project–EU (govt): grant, 201202– 5y FP7 grant €12m 2012-02-13
4SC–BioNTech: investment, 201604 acquisition €650k of all key operating assets + employees of 4SC Discovery GmbH by new BioNTech Small Molecules GmbH 2016-04-29
4SC–Crelux: drug discovery services, 201204– strategic alliance offering integrated drug discovery services by 4SC Discovery + Crelux 2012-04-18
4SC–EU (govt): grant, 201404– €450k grant for 4SC Discovery GmbH as part of the CV genes-at-target project 2014-04-15
4SC–Germany (govt): grant, 201210– research grant €600k for developm personalised cancer drugs within m4 Cluster 2012-10-23
4SC–MC Services: public relations, 201211 service existent for 4SC AG 2012-11-08
4SC–SEVERAL: investment, 200605 capital increase €4,3m placement of 931.3k shares €4.65/share to institutional investors 2006-05-11
4SC–SEVERAL: investment, 201207 capital increase up to 8.4m new shares €12.6m €1.5/share 2012-07-04
4SC–SEVERAL: investment, 201506–201507 cash capital increase €29m (net €27.5m) with 7.25m new shares at €4/share 2015-06-22
4SC–SEVERAL: investment, 201706–201707 cash capital increase €41m with 11.68m new shares at €3.5/share 2017-06-12
4SC–Strüngmann Group: credit, 201406–201612 loan of up to €10m w 8% interest from Santo Holding (Deutschland) GmbH 2014-06-05
4SC–Strüngmann Group: investment, 201506–201507 capital increase €6m in kind 1.5m new shares at €4/share swapping part of shareholder loan from Santo 2015-06-22
4SC–Wellington Partners: investment, 201506–201507 cash capital increase totalling €29m incl €5m from Wellington 2015-06-22
4SC–Yorkville Group: credit, 201402– up to nominally €15m convertible notes to be purchased until 12/16 by YA Global Master SPV Ltd 2014-02-12
4SC–Yorkville Group: credit, 201403 first tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd 2014-03-04
4SC–Yorkville Group: credit, 201409 second tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd 2014-09-03
A & M Labor für Analytik–Thermo Fisher: mass spectrometer, 201002 supply purchase LTQ-Orbitrap-XL mass spectrometer 2010-02-01
Aadi Bioscience–Helsinn: investment, 201705 financing round Series A totalling $23m incl $2m from co-investor Helsinn Investment Fund 2017-05-08
Aadi Bioscience–SEVERAL: investment, 201705 financing round Series A $23m led by Hermed Capital with Celgene + Vivo Capital + Helsinn et al 2017-05-08
AB2 Bio–SEVERAL: investment, 201601 financing round Series B CHF21m ($21m) from existent + new investors 2016-01-11
ABAC Therapeutics–SEVERAL: investment, 201802 financing round Series A €16m led by Pontifax + incl GHSF + Caixa Capital Risc + Debiopharm + Ferrer 2018-02-15
ABBA Therapeutics–Ligand: transgenic animal technology, 201603– license to use OmniAb platform to develop MAbs + bi-specific ABs 2016-03-28
Abbott–Axis-Shield: anti-CCP test, 201110 license existent 2011-10-21
Abbott–Biocartis: molecular diagnostics, 201409 collab existent development of diagnostic tests with Abbott Molecular 2014-09-12
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie 2014-07-01
AbbVie–BioMed X: pharma research, 201503– collab €na new BioMed X research group to discover Alzheimer’s treatment 2015-03-30
AbbVie–Boehringer: therap antibodies, 201603– collab + acqu ww rights BI 655066 + BI 655064 for $595m upfront + undisclosed milestones + royalties 2016-03-07
AbClon–Pepperprint: peptide microarrays, 201302– distribution with marketing + sales rights for Pepperprint products in Korea 2013-04-29
abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals 2018-03-01
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF 2017-12-11
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management 2013-01-01
ABF–Genedata: bioinformatics, 201707– supply expansion use of Genedata Selector by AB Enzymes for decision support 2017-07-11
Abimed–Kinesis: investment, 200801 acquisition 2008-01-01
Abionic–SEVERAL: investment, 201205 financing round Series A CHF3.5m from local VCs + business angels 2012-05-01
Abionic–SEVERAL: investment, 201410 financing round Series B CHF3.8m 2014-10-01
Ablynx–Hoffmann Eitle: legal services, 2010–201501 representation of Ablynx in patent dispute w Domantis by Hoffmann Eitle Munich 2010-01-01
Ablynx–Sanofi: investment, 201801–201806 acquisition recommended cash tender offer €3.9b with €45/share 2018-01-29
Abunda Nutrition–Evolva: food ingredients, 201010– collab expansion + extension €na 2y research production methods for high-value food ingredients 2010-10-25
Abunda Nutrition–Evolva: investment, 201104– acquisition merger announced for 25m shares = 12.9% post transaction, fully diluted 2011-04-05
Abviris–High-Tech Gründerfonds: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Abviris–Schleswig-Holstein (govt): investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Abviris–SEVERAL: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
AbVitro–Juno Therapeutics: investment, 201601 acquisition $78m in cash + 1.289m shares of Juno stock 2016-01-11
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
AC Immune–Michael J Fox Foundation: grant, 201502 research grant €na for developm of PET tracers for alpha-synuclein protein in Parkinson diagnosis 2015-02-12
AC Immune–SEVERAL: investment, 200901 financing round Series C CHF40m from existing investors 2009-01-26
AC Immune–SEVERAL: investment, 201401 financing round Series D CHF20m from existent private investors 2014-01-09
AC Immune–SEVERAL: investment, 201605 private financing round Series E CHF42.7m 2016-05-09
AC Immune–SEVERAL: investment, 201609 US IPO $66m net $57.8m net with 6m common shares at $11/share at Nasdaq 2016-09-13
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare 2011-03-31
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures 2011-03-31
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare 2011-03-31
Academy of Sciences (AT)–Evotec: drug discovery + development, 200904– collab IMBA with European ScreeningPort 2009-04-28
Accovion–Clinipace: investment, 201504 acquisition of Accovion from HeidelbergCapital + Creathor Venture + management 2015-04-10
Accurate Mass Scientific–CovalX: mass spectrometry, 201507– collab AMS new Australian distributor of CovalX High-Mass systems + CRO analytics services 2015-07-15
Ace Animals–Sigma-Aldrich: investment, 201003 acquisition €na 2010-03-16
ACIB–Biokatalayse2021 Cluster: industrial biotechnology, 201106– strategic alliance 2011-06-15
ACIB–Ionicon: mass spectrometry, 203101 collab existent Ionicon is a partner an ACIB providing PRT-MS technology 2014-01-21
Acino–Arpida: iclaprim, 200911 acquisition CHF2.1m of all assets related to iclaprim by Acino Holding AG 2009-11-04
Acino–Avista Capital: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital 2013-10-02
Acino–Nordic Capital: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital 2013-10-02
Acino–SEVERAL: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital 2013-10-02
Acousia Therapeutics–Boehringer: investment, 201805 financing round Series B totalling €10m incl existing + co-investor BIVF 2018-05-14
Acousia Therapeutics–Bregua Corp: investment, 201805 financing round Series B totalling €10m incl new + co-investor Bregua Corp 2018-05-14
Acousia Therapeutics–Creathor Venture: investment, 201805 financing round Series B totalling €10m incl new + co-investor Creathor Venture 2018-05-14
Acousia Therapeutics–Germany (govt): investment, 201805 financing round Series B totalling €10m incl existing + co-investor KfW 2018-05-14
Acousia Therapeutics–Instinctif Partners: public relations, 201805 service existent by Instinctif 2018-05-14
Acousia Therapeutics–LBBW: investment, 201805 financing round Series B totalling €10m incl lead + new investor LBBW Venture Capital 2018-05-14
Acousia Therapeutics–SEVERAL: investment, 201612 financing round €2.5m led by BIVF + incl KfW + Axxam 2016-12-14
Acousia Therapeutics–SEVERAL: investment, 201805 financing round Series B €10m led by new investor LBBW Venture Capital 2018-05-14
aCROnordic–Manipal: investment, 201103–2012 acquisition of aCROnordic A/S by Ecron Acunova GmbH 2011-03-28
Actelion–Amgen: investment, 201011– RUMOURS OF possible acquisition offer by Amgen NO OFFER MADE YET 2010-11-17
Actelion–Enamine: chemical compound library, 2005– collab supply of screening compound library to Actelion 2005-01-01
Actelion–Enamine: chemical compound library, 201701– collab expansion supply of screening compound library to Actelion 2017-01-23
Actelion–JnJ: investment, 201701–201706 acquisition $30b all-cash tender offer funded w JnJ cash held outside of US 2017-01-26
Actelion–Max Planck: vaccine technology, 201506 license excl synthetic carbohydrate vaccines for new Vaxillion joint venture from + with Max Planck 2015-06-26
Actelion–Qlucore: bioinformatics, 201507– license 3y to Omics Explorer s/w after using it since 2011 2015-07-01
Actelion–Reveragen: vamorolone, 201611– excl license option for Actelion 2016-11-03
Acticor Biotech–Merck (DE): rec protein production, 201612– supply Provantage End-to-End Services for developm + manufacturing of Fab 2016-12-05
Activaero–MC Services: public relations, 201304 service existent for Activaero GmbH 2013-04-23
Activaero–SEVERAL: investment, 201102 financing round €5m led by LSP Life Sciences Partners with €3.5m 2011-02-02
Activaero–Vectura: investment, 201403 acquisition €130m with €45m cash upfront + €35m in Aug 2015 + €50m in shares 2014-03-13
Active Biotech–Evotec: drug discovery services, 201003– service €na identification of small molecule leads by HT screening for specific target 2010-03-11
Active Biotech–Evotec: drug discovery services, 201106– service €na medicinal chemistry services after successful HTS 2011-06-06
Active Biotech–Evotec: drug discovery services, 201204– service €na expansion medicinal chemistry services drug optimisation 2012-04-26
Active Spectrum–Bruker Corp: investment, 201612 acquisition €na of Active Spectrum by Bruker 2016-12-16
Ada Health–SEVERAL: investment, financing round €40m led by Access Industries (Len Blavatnik) 2017-10-31
Adaptimmune–Ally Bridge Group: investment, 201702 existent investment of ABG 2017-02-23
ADC Therapeutics–Celtic Therapeutics: investment, 2012 acquisition of majority share in newly founded ADC Therapeutics 2012-01-01
ADC Therapeutics–Instinctif Partners: public relations, 201509 service existent by Instinctif Partners for ADCT 2015-09-02
ADC Therapeutics–SEVERAL: investment, 201509 financing round $80m of ADC Therapeutics incl Auven + AstraZeneca et al 2015-09-02
ADC Therapeutics–SEVERAL: investment, 201610 private financing round $105m incl Auven Therapeutics + Wild Family Office + AstraZeneca 2016-10-18
1 2 3 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top